RT Journal Article SR Electronic T1 Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. JF Annals of the Rheumatic Diseases JO Ann Rheum Dis FD BMJ Publishing Group Ltd and European League Against Rheumatism SP 43 OP 47 DO 10.1136/ard.47.1.43 VO 47 IS 1 A1 N J McHugh A1 M Csuka A1 H Watson A1 G Belcher A1 A Amadi A1 E F Ring A1 C M Black A1 P J Maddison YR 1988 UL http://ard.bmj.com/content/47/1/43.abstract AB Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.